uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394
Debt
Debt-to-Equity Ratio0.06
Current Ratio8.36
Quick Ratio8.36
Price-To-Earnings
Trailing P/E Ratio-9.76
Forward P/E Ratio-11.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.11 million
Price / Sales79.84
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book9.69
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-677.98%
Return on Equity-72.12%
Return on Assets-36.31%
Miscellaneous
Employees202
Outstanding Shares37,250,000
Market Cap$1.36 billion
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) announced its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.04. The biotechnology company earned $3.05 million during the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
11 brokerages have issued 1-year price targets for Uniqure's stock. Their forecasts range from $22.00 to $63.00. On average, they anticipate Uniqure's stock price to reach $46.2222 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (10/17/2018)
- 3. HC Wainwright analysts commented, "Our new $48 price target, is based on a 13-year DCF analysis that incorporates rNPV of two pipeline products, including: (1) Hemophilia B at a 70% POS driven by company’s clinical update as of September 23, 2018, vs. prior 65%; and (2) 5% POS. We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $981M, upped from $820M previously, during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents a 50% of the overall commercial opportunity." (9/24/2018)
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Amarin (AMRN), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Madrigal Pharmaceuticals (MDGL), Horizon Pharma (HZNP) and Array Biopharma (ARRY).
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 46)
- Dr. Sander Van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & Gen. Mang. of Amsterdam (Age 64)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 52)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operating Officer (Age 59)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (0.14%). Company insiders that own Uniqure stock include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor, Matthew C Kapusta and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co.. Company insiders that have sold Uniqure company stock in the last year include Christian Klemt, David Schaffer, Deventer Sander Van, Maria E Cantor, Matthew C Kapusta and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $28.10.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.36 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
